Shares of Catabasis Pharmaceuticals Inc (NASDAQ:CATB) have earned an average recommendation of “Buy” from the seven analysts that are presently covering the stock, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $5.67.
Several equities research analysts have recently weighed in on the stock. Wedbush increased their target price on shares of Catabasis Pharmaceuticals from $5.00 to $6.00 and gave the stock an “outperform” rating in a research note on Tuesday. Zacks Investment Research downgraded shares of Catabasis Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, January 29th. Finally, Citigroup upgraded shares of Catabasis Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $3.00 target price for the company in a research note on Monday, November 20th.
Shares of Catabasis Pharmaceuticals (NASDAQ:CATB) traded up $0.06 on Friday, hitting $2.00. 119,278 shares of the stock traded hands, compared to its average volume of 1,092,540. Catabasis Pharmaceuticals has a twelve month low of $1.09 and a twelve month high of $3.78. The firm has a market capitalization of $56.91, a P/E ratio of -1.55 and a beta of 0.80.
Catabasis Pharmaceuticals (NASDAQ:CATB) last announced its earnings results on Thursday, March 15th. The biotechnology company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.07. The business had revenue of $0.25 million for the quarter, compared to analyst estimates of $0.25 million. analysts anticipate that Catabasis Pharmaceuticals will post -1.09 earnings per share for the current year.
A number of hedge funds and other institutional investors have recently bought and sold shares of CATB. Oppenheimer & Co. Inc. raised its holdings in Catabasis Pharmaceuticals by 40.8% during the third quarter. Oppenheimer & Co. Inc. now owns 169,000 shares of the biotechnology company’s stock worth $358,000 after purchasing an additional 49,000 shares in the last quarter. Geode Capital Management LLC raised its holdings in Catabasis Pharmaceuticals by 146.1% during the fourth quarter. Geode Capital Management LLC now owns 76,612 shares of the biotechnology company’s stock worth $114,000 after purchasing an additional 45,476 shares in the last quarter. Renaissance Technologies LLC raised its holdings in Catabasis Pharmaceuticals by 167.2% during the fourth quarter. Renaissance Technologies LLC now owns 468,700 shares of the biotechnology company’s stock worth $698,000 after purchasing an additional 293,300 shares in the last quarter. Finally, Deutsche Bank AG purchased a new position in Catabasis Pharmaceuticals during the fourth quarter worth about $335,000. 34.39% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: “Brokerages Set Catabasis Pharmaceuticals Inc (CATB) Target Price at $5.33” was first posted by Stock Observer and is the property of of Stock Observer. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright law. The correct version of this report can be read at https://www.thestockobserver.com/2018/03/20/brokerages-set-catabasis-pharmaceuticals-inc-catb-target-price-at-5-33.html.
Catabasis Pharmaceuticals Company Profile
Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.
Receive News & Ratings for Catabasis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.